Substituted 5-benzyl-2-phenyl-5H-imidazo[4,5-c]pyridines: A new class of pestivirus inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 20, 2006, Pages 5345-5349

  Puerstinger, Gerhard ^a   Paeshuyse, Jan ^b   Herdewijn, Piet ^b   Rozenski, Jef ^b   De Clercq, Erik ^b   Neyts, Johan ^b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antiviral; BVDV; HCV; Imidazo 4,5 c pyridines; Pestivirus inhibitors

Indexed keywords

5 BENZYL 2 PHENYL 5H IMIDAZO[4,5 C]PYRIDINE DERIVATIVE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BOVINE DIARRHEA VIRUS; CONTROLLED STUDY; CYTOTOXICITY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PESTIVIRUS; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

ANTIVIRAL AGENTS; CELL LINE; DIARRHEA VIRUSES, BOVINE VIRAL; IMIDAZOLES; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PYRIDINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

BOVINE VIRAL DIARRHEA VIRUS 1; HEPATITIS C VIRUS; PESTIVIRUS;

EID: 33748325736     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.07.081     Document Type: Article

References (21)

1. Lindenbach B.D., and Rice C.M. In: Knipe D.M., Howley P.M., Griffin D.E., Martin M.A., Lamb R.A., Roizman B., and Straus S.E. (Eds). Fields Virology (2001), Lippincott Williams & Wilkins, Philadelphia 991-1041
2. Houe H. Biologicals 31 (2003) 137
3. Edwards S., Fukusho A., Lefevre P.C., Lipowski A., Pejsak Z., Roehe P., and Westergaard J. Vet. Microbiol. 73 (2000) 103
4. Greiser-Wilke I., Grummer B., and Moennig V. Biologicals 31 (2003) 113
5. Stegeman A., Elbers A., de Smit H., Moser H., Smak J., and Pluimers F. Vet. Microbiol. 73 (2000) 183
6. Stringfellow D.A., Riddell K.P., Givens M.D., Galik P.K., Sullivan E., Dykstra C.C., Robl J., and Kasinathan P. Theriogenology 63 (2005) 1004
7. Durantel D., Carrouee-Durantel S., Branza-Nichita N., Dwek R.A., and Zitzmann N. Antimicrob. Agents Chemother. 48 (2004) 497
8. Givens M.D., Stringfellow D.A., Dykstra C.C., Riddell K.P., Galik P.K., Sullivan E., Robl J., Kasinathan P., Kumar A., and Boykin D.W. Antiviral Res. 64 (2004) 113
9. Buckwold V.E., Beer B.E., and Donis R.O. Antiviral Res. 60 (2004) 1
10. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., McKeating J.A., and Rice C.M. Science 309 (2005) 623
11. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., and Liang T.J. Nat. Med. 11 (2005) 791
12. Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D.R., Wieland S.F., Uprichard S.L., Wakita T., and Chisari F.V. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 9294
13. Thomson B.J., and Finch R.G. Clin. Microbiol. Infect. 11 (2005) 86
14. Lauer G.M., and Walker B.D. N. Eng. J. Med. 345 (2001) 41
15. 50) was defined as the concentration that inhibited the proliferation of exponentially growing cells by 50% and was calculated using linear interpolation.
16. Paeshuyse J., Leyssen P., Mabery E., Boddeker N., Vrancken R., Froeyen M., Ansari I.H., Dutartre H., Rozenski J., Gil L.H.V.G., Letellier C., Lanford R., Canard B., Koenen F., Kerkhofs P., Donis R.O., Herdewijn P., Watson J., De Clercq E., Puerstinger G., and Neyts J. J. Virol. 80 (2006) 149
17. 6): 171.4, 155.8, 145.5, 135.8, 135.0, 131.8, 131.4, 130.8, 130.0, 129.2, 128.3, 127.6, 121.8, 112.3, 60.3.
18. Baginski S.G., Pevear D.C., Seipel M., Sun S.C., Benetatos C.A., Chunduru S.K., Rice C.M., and Collett M.S. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 7981
19. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., and Bartenschlager R. Science 285 (1999) 110
20. Letellier C., Kerkhofs P., Wellemans G., and Vanopdenbosch E. Vet. Microbiol. 64 (1999) 155
21. Vassilev V.B., and Donis R.O. Virus Res. 69 (2000) 95